PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ensitrelvir→

Ensitrelvir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2647530-73-0
Molecular formula
C22H17ClF3N9O2
Molecular weight
531.88 g/mol
Drug class
Oral SARS-CoV-2 3-chymotrypsin-like protease (3CLpro/Mpro) inhibitorantiviral
Mechanism of action
Inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication and assembly of functional viral proteins.
Indications / reported uses
  • Post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older under the EU-authorised ZOKOVEA indication (EU marketing authorisation issued 18 September 2026). Do not extrapolate this indication to treatment of established COVID-19 or other jurisdictions without a corresponding authorisation.

Sources: EMA EPAR — Zokovea, EU marketing authorisation 18 September 2026 · European Commission Union Register — Zokovea product indication · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ensitrelvir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ensitrelvir Permitted Daily Exposure (PDE) report (the Ensitrelvir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ensitrelvir Occupational Exposure Limit (OEL) report (the Ensitrelvir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.